Trade Aquestive Therapeutics, Inc. - AQST CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0330 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.0785 |
| Open | 3.0685 |
| 1-Year Change | 16.89% |
| Day's Range | 3.0285 - 3.0985 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 3.0785 | -0.0200 | -0.65% | 3.0985 | 3.1085 | 3.0185 |
| Jan 16, 2025 | 3.0785 | -0.1800 | -5.52% | 3.2585 | 3.2585 | 3.0685 |
| Jan 15, 2025 | 3.2285 | 0.1700 | 5.56% | 3.0585 | 3.2285 | 3.0385 |
| Jan 14, 2025 | 3.0185 | -0.0800 | -2.58% | 3.0985 | 3.2485 | 2.9885 |
| Jan 13, 2025 | 3.0885 | 0.0600 | 1.98% | 3.0285 | 3.1385 | 2.9385 |
| Jan 10, 2025 | 3.0585 | 0.1200 | 4.08% | 2.9385 | 3.0685 | 2.9385 |
| Jan 8, 2025 | 3.1185 | -0.0800 | -2.50% | 3.1985 | 3.2285 | 3.0485 |
| Jan 7, 2025 | 3.2085 | -0.0400 | -1.23% | 3.2485 | 3.3985 | 3.1785 |
| Jan 6, 2025 | 3.2785 | -0.2600 | -7.35% | 3.5385 | 3.5585 | 3.2485 |
| Jan 3, 2025 | 3.5585 | -0.0600 | -1.66% | 3.6185 | 3.7485 | 3.5585 |
| Jan 2, 2025 | 3.6485 | 0.1000 | 2.82% | 3.5485 | 3.7685 | 3.5085 |
| Dec 31, 2024 | 3.5485 | 0.0600 | 1.72% | 3.4885 | 3.6985 | 3.4585 |
| Dec 30, 2024 | 3.5085 | 0.1100 | 3.24% | 3.3985 | 3.5185 | 3.3485 |
| Dec 27, 2024 | 3.5085 | -0.0400 | -1.13% | 3.5485 | 3.5885 | 3.3785 |
| Dec 26, 2024 | 3.6385 | 0.1700 | 4.90% | 3.4685 | 3.6385 | 3.4485 |
| Dec 24, 2024 | 3.4985 | -0.0500 | -1.41% | 3.5485 | 3.5885 | 3.4185 |
| Dec 23, 2024 | 3.5685 | -0.0200 | -0.56% | 3.5885 | 3.6285 | 3.4785 |
| Dec 20, 2024 | 3.6285 | 0.0900 | 2.54% | 3.5385 | 3.7485 | 3.4885 |
| Dec 19, 2024 | 3.6085 | 0.0500 | 1.41% | 3.5585 | 3.7385 | 3.4985 |
| Dec 18, 2024 | 3.4285 | -0.4000 | -10.45% | 3.8285 | 3.8285 | 3.3585 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Aquestive Therapeutics, Inc. Company profile
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing differentiated products which leverage PharmFilm. Its late-stage product pipeline focused on the treatment of central nervous system (CNS), diseases and an earlier stage pipeline including treatment of anaphylaxis. Its commercialized licensed product is Suboxone, a sublingual film formulation of buprenorphine and naloxone, for the treatment of opioid dependence. Its CNS portfolio focused on epilepsy includes, Sympazan an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome (LGS). Its portfolio also includes Suboxone a sublingual film formulation of buprenorphine and naloxone, respectively an opioid agonist and antagonist for the treatment of opioid dependence.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aquestive Therapeutics Inc revenues increased 11% to $50.8M. Net loss increased 26% to $70.5M. Revenues reflect Ex-United States segment increase of 63% to $8M, United States segment increase of 5% to $42.9M. Higher net loss reflects Interest expense related to the sale increase from $2M to $12.4M (expense), Stock-based Compensation in R&D increase of 21% to $881K (expense).
Equity composition
Common Stock $.01 Par, Shares auth. and o/s after the offering: 100M auth., 15,029,412 issd. Insiders own approx. 1% (after the IPO). IPO: TBA. 4M shares Offered. 03/08, IPO withdrawn.
| Industry: | Pharmaceuticals (NEC) |
30 Technology Dr
WARREN
NEW JERSEY 07059-5166
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com